# Multi-Arm Feasibility Study Evaluating OTX-TP Compared to Timolol in Treatment of Subjects With Open Angle Glaucoma

> **NCT01845038** · PHASE1 · COMPLETED · sponsor: **Ocular Therapeutix, Inc.** · enrollment: 41 (actual)

## Conditions studied

- Glaucoma

## Interventions

- **DRUG:** OTX-TPa ~4µg/day over 2 mos. with natural tears drops
- **DRUG:** OTX-TPb ~3µg/day over 3 months with natural tears drops
- **DRUG:** Timolol Maleate (0.5%) dosed twice daily with punctum plug without drug

## Key facts

- **NCT ID:** NCT01845038
- **Lead sponsor:** Ocular Therapeutix, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04
- **Primary completion:** 2014-03
- **Final completion:** 2014-05
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2016-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01845038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01845038, "Multi-Arm Feasibility Study Evaluating OTX-TP Compared to Timolol in Treatment of Subjects With Open Angle Glaucoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01845038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*